Skip to main content
. 2022 Feb 16;10(2):466. doi: 10.3390/biomedicines10020466
PD Parkinson’s disease
SNpc substantia nigra pars compacta
SNpr substantia nigra pars reticulata
VTA ventral tegmental area
V1 visual cortex
M1 motor cortex
PFC prefrontal cortex
DLStr dorsolateral striatum
VMStr ventromedial striatum
Amy amygdala
Thal Thalamus
NR nucleus ruber
DHip dorsal hippocampus
VHip ventral hippocampus
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
6-OHDA 6-hydroxydopamine
VTA ventral tegmental area
DMSO dimethyl sulfoxide
mNSS modified neurological severity scores
PBS phosphate-buffered saline
LPO lipid peroxidation
CL Chemiluminescence
DA Dopamine
5-HT Serotonin
NA Noradrenaline
DOPAC 3,4-dihydroxyphenylacetic acid
3-MT 3-methoxytyramine
HVA homovanillic acid
5-HIAA 5-hydroxyindoleacetic acid
HPLC-ED high-performance liquid chromatography with electrochemical detection
TH tyrosine hydroxylase
DAPI 4′,6-diamidino-2-phenylindole
NADH nicotinamide adenine dinucleotide